Photo taken from Benedetta Pellegrino/X
Jul 9, 2024, 22:15
Benedetta Pellegrino: Validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1
Benedetta Pellegrino, Resident in Medical Oncology at the University Hospital of Parma, shared on X:
“Discover our latest study on the validation of the HRD RAD51 assay as a predictive biomarker for VUS pathogenicity in BRCA1 in breast and ovarian cancer! ”
Read further.
Source: Benedetta Pellegrino/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 25, 2025, 09:24
Apr 25, 2025, 09:19
Apr 25, 2025, 09:03
Apr 25, 2025, 08:56
Apr 25, 2025, 08:46
Apr 25, 2025, 08:32